NVO Novo Nordisk A/S
52.52
-0.16 -0%
Previous Close
52.68
Open
52.63
Price To Book
16.01
Market Cap
124,202,079,875
Shares
2,364,853,006
Volume
780,385
Short Ratio
4.19
Av. Daily Volume
1,391,938
NewsSee all news
-
New international study: The hidden burden of diabetes on family members revealed
New international study shows 64 per cent of family members of peoplewith diabetes are worried or anxious about the risk of low blood sugar MISSISSAUGA, ON, Sept. 10, 2019 /CNW/ - People
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
FDA approval announced September 20, 2019.
Semaglutide - oral - PIONEER
Type 2 diabetes
Phase 3 trial to be initiated 4Q 2019.
Concizumab
Hemophilia A
Approval announced August 25, 2017.
Victoza (liraglutide)
Type 2 diabetes
Approved September 29, 2017.
Fiasp (fast-acting insulin aspart)
Type 1 and type 2 diabetes
Phase 3 trial initiated 2Q 2019.
Somapacitan (NN8640)
Growth Hormone Deficiency (GHD)
Phase 2 data released 2Q 2019.
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes
Approval announced December 5, 2017.
Semaglutide
Type 2 diabetes
Approval announced May 31, 2017.
Nonacog beta pegol
haemophilia B
FDA Approval announced February 19, 2019.
N8-GP
Hemophilia A
Phase 2 trial initiated 1Q 2019.
AM833
Obesity
Latest News
-
New international study: The hidden burden of diabetes on family members revealed
New international study shows 64 per cent of family members of peoplewith diabetes are worried or anxious about the risk of low blood sugar MISSISSAUGA, ON, Sept. 10, 2019 /CNW/ - People